Download PDF
Semin Respir Crit Care Med 2020; 41(06): 842-850
DOI: 10.1055/s-0040-1714379
Review Article

Nonantibiotic Pharmacological Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations

Francesco Vasques
1   Department of Adult Critical Care, Guy's and St. Thomas' NHS Foundation Trust, King’s Health Partners, London, United Kingdom
2   Division of Centre of Human Applied Physiological Sciences, King's College London, London, United Kingdom
,
Luigi Camporota
1   Department of Adult Critical Care, Guy's and St. Thomas' NHS Foundation Trust, King’s Health Partners, London, United Kingdom
2   Division of Centre of Human Applied Physiological Sciences, King's College London, London, United Kingdom
,
Nicholas A. Barrett
1   Department of Adult Critical Care, Guy's and St. Thomas' NHS Foundation Trust, King’s Health Partners, London, United Kingdom
2   Division of Centre of Human Applied Physiological Sciences, King's College London, London, United Kingdom
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Severe, acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a rapid deterioration of the respiratory symptoms of patients with COPD, requiring hospital admission and escalation of pharmacological and nonpharmacological care including the more severe cases of respiratory failure and admission to an intensive care unit (ICU). These events severely impact patients' quality of life and prognosis. This review will describe the nonantibiotic, pharmacological treatment options available for critically ill patients with AECOPD. The aim of treatment is to alleviate symptoms, improve patient's functional and respiratory status, reduce mortality, reduce the risk or the duration of invasive mechanical ventilation, and prevent reexacerbations. Inhaled bronchodilators (i.e., short-acting β2-agonists and anticholinergics) and systemic corticosteroids are the main drugs used in the treatment of AECOPD. These drugs are also used in the treatment of stable COPD and in the treatment of AECOPD patients in the non-ICU or community setting. Other drugs are essentially only used in the ICU setting such as inhaled anesthetic agents, ketamine, intravenous methylxanthines, and magnesium. Finally, recently developed drugs, such as the specific phosphodiesterase-4 inhibitors, may play a role in the prevention of relapsing AECOPD following a critical event than the treatment of the exacerbation itself. Although they significantly improve the survival of critically ill patients with AECOPD, none of available drugs, alone or combined, is able to significantly modify the prognosis of patients with COPD. This remains an open challenge for the current and future generations of researchers and clinicians.

Keywords

AECOPD - severe COPD exacerbation - pharmacological treatment COPD - bronchodilators - corticosteroids - roflumilast


Publication History

Article published online:
29 July 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 2020 Gold Reports. 2020 global strategy for prevention, diagnosis and management of COPD. Available at: https://goldcopd.org/gold-reports/ . Accessed July 01, 2020
    Google Scholar
  • 2 López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016; 21 (01) 14-23
    CrossrefPubMedGoogle Scholar
  • 3 Soriano JB, Lamprecht B, Ramírez AS. et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med 2015; 3 (06) 443-450
    CrossrefPubMedGoogle Scholar
  • 4 Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60 (11) 925-931
    CrossrefPubMedGoogle Scholar
  • 5 Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163 (10) 1180-1186
    CrossrefPubMedGoogle Scholar
  • 6 Nannini LJ. Hospitalization due to COPD exacerbation. Chest 2012; 142 (06) 1697
    CrossrefPubMedGoogle Scholar
  • 7 Hurst JR, Vestbo J, Anzueto A. et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363 (12) 1128-1138
    CrossrefPubMedGoogle Scholar
  • 8 Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011; 37 (03) 508-515
    CrossrefPubMedGoogle Scholar
  • 9 NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng115 . Accessed July 01, 2020
    Google Scholar
  • 10 McCrory DC, Brown CD. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2001; (02) CD002984
    PubMedGoogle Scholar
  • 11 Kopsaftis ZA, Sulaiman NS, Mountain OD, Carson-Chahhoud KV, Phillips PA, Smith BJ. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review. Syst Rev 2018; 7 (01) 213
    CrossrefPubMedGoogle Scholar
  • 12 Amin AN, Bollu V, Stensland MD, Netzer L, Ganapathy V. Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2018; 75 (06) 359-366
    CrossrefPubMedGoogle Scholar
  • 13 van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev 2016; (08) CD011826
    PubMedGoogle Scholar
  • 14 Bardsley G, Pilcher J, McKinstry S. et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. BMC Pulm Med 2018; 18 (01) 157
    CrossrefPubMedGoogle Scholar
  • 15 O'Driscoll BR, Howard LS, Earis J, Mak V. British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax 2017; 72 (Suppl. 01) ii1-ii90
    CrossrefPubMedGoogle Scholar
  • 16 Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319 (08) 486-494
    CrossrefPubMedGoogle Scholar
  • 17 Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Dey Combination Solution Study Group. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998; 65 (05) 354-362
    CrossrefPubMedGoogle Scholar
  • 18 COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105 (05) 1411-1419
    CrossrefPubMedGoogle Scholar
  • 19 Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25 (04) 470-473
    CrossrefPubMedGoogle Scholar
  • 20 NICE. Asthma: diagnosis, monitoring and chronic asthma management. Available at: https://www.nice.org.uk/guidance/ng80 . Accessed July 01, 2020
    Google Scholar
  • 21 Bhatt SP, Khandelwal P, Nanda S, Stoltzfus JC, Fioravanti GT. Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2008; 102 (07) 999-1003
    CrossrefPubMedGoogle Scholar
  • 22 Gumus A, Haziroglu M, Gunes Y. Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulm Med 2014; 2014: 329476
    CrossrefPubMedGoogle Scholar
  • 23 Shivanthan MC, Rajapakse S. Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Ann Thorac Med 2014; 9 (02) 77-80
    CrossrefPubMedGoogle Scholar
  • 24 Edwards L, Shirtcliffe P, Wadsworth K. et al; Magnesium COPD Study Team. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax 2013; 68 (04) 338-343
    CrossrefPubMedGoogle Scholar
  • 25 Barr RG, Rowe BH, Camargo Jr CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003; 327 (7416): 643
    CrossrefPubMedGoogle Scholar
  • 26 Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J 2017; 50 (01) 1700158
    CrossrefPubMedGoogle Scholar
  • 27 Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015; 385 (9971): 857-866
    CrossrefPubMedGoogle Scholar
  • 28 Wedzicha JAEC-C, Miravitlles M, Hurst JR. et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49 (03) 1600791
    CrossrefPubMedGoogle Scholar
  • 29 Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016; 71 (08) 759-761
    CrossrefPubMedGoogle Scholar
  • 30 Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; (09) CD001288
    PubMedGoogle Scholar
  • 31 Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354 (9177): 456-460
    CrossrefPubMedGoogle Scholar
  • 32 Niewoehner DE, Erbland ML, Deupree RH. et al; Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340 (25) 1941-1947
    CrossrefPubMedGoogle Scholar
  • 33 Alía I, de la Cal MA, Esteban A. et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171 (21) 1939-1946
    CrossrefPubMedGoogle Scholar
  • 34 Abroug F, Ouanes-Besbes L, Fkih-Hassen M. et al. Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J 2014; 43 (03) 717-724
    CrossrefPubMedGoogle Scholar
  • 35 de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132 (06) 1741-1747
    CrossrefPubMedGoogle Scholar
  • 36 Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189 (09) 1052-1064
    CrossrefPubMedGoogle Scholar
  • 37 Leuppi JD, Schuetz P, Bingisser R. et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309 (21) 2223-2231
    CrossrefPubMedGoogle Scholar
  • 38 Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018; 3: CD006897
    PubMedGoogle Scholar
  • 39 Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119 (03) 726-730
    CrossrefPubMedGoogle Scholar
  • 40 Volta CA, Alvisi V, Petrini S. et al. The effect of volatile anesthetics on respiratory system resistance in patients with chronic obstructive pulmonary disease. Anesth Analg 2005; 100 (02) 348-353
    CrossrefPubMedGoogle Scholar
  • 41 Swenson ER. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression. Eur Respir J 1998; 12 (06) 1242-1247
    CrossrefPubMedGoogle Scholar
  • 42 Libório AB, Noritomi DT, Leite TT, de Melo Bezerra CT, de Faria ER, Kellum JA. Increased serum bicarbonate in critically ill patients: a retrospective analysis. Intensive Care Med 2015; 41 (03) 479-486
    CrossrefPubMedGoogle Scholar
  • 43 Faisy C, Meziani F, Planquette B. et al; DIABOLO Investigators. Effect of acetazolamide vs placebo on duration of invasive mechanical ventilation among patients with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA 2016; 315 (05) 480-488
    CrossrefPubMedGoogle Scholar
  • 44 Bahloul M, Chaari A, Tounsi A. et al. Impact of acetazolamide use in severe exacerbation of chronic obstructive pulmonary disease requiring invasive mechanical ventilation. Int J Crit Illn Inj Sci 2015; 5 (01) 3-8
    CrossrefPubMedGoogle Scholar
  • 45 Adamson R, Swenson ER. Acetazolamide use in severe chronic obstructive pulmonary disease. pros and cons. Ann Am Thorac Soc 2017; 14 (07) 1086-1093
    PubMedGoogle Scholar
  • 46 Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med 2004; 4: 13
    CrossrefPubMedGoogle Scholar